NextGen Bioscience, Inc., a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers. The Company is focused on the discovery, development and commercialization of novel therapeutics to fight prostate and breast cancer. All of NextGen’s product candidates target disease indications which represent a significant unmet need, as well as having substantial potential market values.
NextGen’s business model is to acquire promising new patented technologies in the fields of cancer and infectious disease, to add significant value to these by advancing them through toxicological assessment or Phase I clinical trials and then outlicensing the technology to a larger partner who has the necessary infrastructure to take the products to market. All acquisition candidates are underpinned by patent applications or granted patents which confer protection in the major jurisdictions worldwide. Revenues generated from licensing activities will then be reinvested in research and development by NextGen to benefit patients, partners and the Company’s investors.
Cancer treatments, NextGen’s target market, represents the largest disease market, exploding at a 20% growth rate each year and reaching a phenomenal global market volume of approximately $30 Billion. In the event that NextGen’s proprietary product candidates successfully target significant unmet needs, and based upon deals achieved by other successful drug targets in the industry, NextGen can expect up to $100 million in milestone payments per licensed product during clinical trials, and up to $400 million per annum in the years (up to 20 years) following commercialization. With market growth, NextGen’s licensing fees could grow to $700 million per annum per product. This represents a significant catalyst for company growth which will in turn greatly benefit stakeholders.
NextGen is rapidly building its portfolio of proprietary biotechnology. The Company’s patented drug and product portfolio includes a prostate cancer target and a breast cancer target as well as a promising acquisition pipeline. These first two anti-tumor drug candidates, Prostaganin (prostate cancer) and Tetanolic (breast cancer), both have incredible market potential as they may ultimately eliminate the need for surgery and chemotherapy and possess no side effects.
Based in London, NextGen is able to keep operating costs to a minimum by outsourcing all product development work to established specialist service providers and Universities to add significant value, but at low cost. NextGen’s experienced Management team and Scientific Advisory Board will guide and direct development of the products to add maximum value.
Additionally, NextGen has identified a number of promising potential acquisitions of R&D projects, which can be acquired immediately at costs significantly below past investments made in them. These, and other future acquisitions, will ensure that NextGen’s pipeline of products are maintained at the forefront of scientific and medical developments, again, bringing maximum benefit to stakeholders.
Key parameters differentiating NextGen from other biotechnology companies –
* Corporate focus
* World-class Management Team and Scientific Advisory Board
* Potential value
* Pipeline of acquisition candidates
* Blockbuster Potential Strategy
* Leverage of resources
* Organizational Flexibility and low fixed overheads
* Opportunistic approach
NextGen’s Corporate focus is devoted to identification, evaluation and acquisition of drug targets and subsequent value addition to maximize benefits to stakeholders. The Company’s World-class Management Team and Scientific Advisory Board directs product development, each with specialist experience in this field. Potential value is built in the portfolio of pending patent applications for treatment of difficult to treat cancers (NextGen’s proprietary IP). The Pipeline of acquisition candidates being evaluated is derived from global collaborations with other biotechnology companies and Universities. Strategy of acquiring candidates aims to target indications with significant unmet needs and blockbuster market potential. Due to outsourcing strategy, NextGen maintains a Highly Flexible organization and low fixed overheads. The Company obtains Leverage of resources through collaboration with well established service providers and academic laboratories. The Company’s Opportunistic approach is characterized by swift decision making and ability to redirect research and business efforts quickly and at low cost, to maximize partnering activities.
NextGen’s business model of global outsourcing, international collaboration, early stage partnering, the benefit of advice from leading experts in the field and use of regulatory fast-tracking ensures accelerated drug development – and early exit to larger biotech or pharma companies which have the necessary infrastructure to develop the products further.
Today early stage partnering is a core component of both biotech and pharmaceutical business strategy, allowing companies to access promising new and emerging compounds and technologies. Dealmaking in the pharmaceutical industry is constantly growing; big pharmaceutical companies are forecast to receive around 40-50% of their revenue from in-licensed products by 2010 (Pharmalicensing, 2006). The balance of dealmaking activity has also moved, from the later stages of development to the early stages, where deals have not only increased in number but value too. The average early stage deal value has risen from US$65.3 million in 2001 to US$125.1 million in 2005 (Burrill & Company, 2006).
The main target indication area is cancer treatment and in particular:
• Prostate cancer
• Breast cancer
• Colorectal cancer
Researches among cancer biologists identify a subpopulation of cells inside a tumor capable of generating new tumors. These cells share the characteristics of stem cells, which are able to replicate and repair damaged cells and are called cancer stem cells. NextGen’s treatment niche is to target therapies against the cancer stem cells themselves, to prevent recurrence at a later stage. Recent data showed that certain cytokine proteins, such as lnterleukin-4 and lnterleukin-10, actively protect tumor cells from death by exposure to conventional drugs (Stassi et al 2003). NextGen’s technology relates to the identification of cancer stem cells in solid tumors through the use of specific antibodies to target and neutralize the cytokines responsible for protecting the tumors.
An emerging indication area for NextGen is in infectious disease, particularly hospital acquired infections such as MRSA. MRSA infections are becoming more prevalent in healthcare settings: in 1974, MRSA infections accounted for two percent of the total number of infections; in 1995 it was 22 percent; and in 2004 it was 63 percent (US Centers for Disease Control, 2007). The bacteria responsible are increasingly resistant to existing antibiotics. One of NextGen’s potential acquisition candidates will target hospital acquired infections such as MRSA.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC has been compensated 37,000 shares from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. Pentony Enterprises currently holds twenty one thousand shares.
